SEC Company Response from BioPharmX Corp (CIK 0001504167) — Mar 30, 2020
BioPharmX Corp (CIK 0001504167)
Date: March 30, 2020 · CIK: 0001504167 · Accession: 0001104659-20-040019
AI Filing Summary & Sentiment
File numbers found in text: 333-236526
Letter
BioPharmX Corporation
900 E. Hamilton Avenue, Suite 100
Campbell, California 95008
March 30, 2020
VIA EDGAR (CORRESPONDENCE) AND E-MAIL
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: BioPharmX Corporation
Registration Statement on Form S-4
Registration No. 333-236526
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioPharmX Corporation (“Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-4 be accelerated to 2:00 p.m., Washington, D.C. time, on Tuesday, March 31, 2020, or as soon thereafter as is practicable.
The Company hereby acknowledges and confirms its understanding that the Company and its management are responsible for the accuracy and adequacy of the disclosure in the Registration Statement, notwithstanding any review, comments, action or absence of action by the staff of the SEC.
Please call Andrew Schwartz (at 954-468-2452) at Akerman LLP as soon as the Registration Statement has been declared effective.
Thank you for your courtesy and cooperation.
Very Truly Yours,
/s/ Steven M. Bosacki
Show Raw Text
CORRESP 1 filename1.htm BioPharmX Corporation 900 E. Hamilton Avenue, Suite 100 Campbell, California 95008 March 30, 2020 VIA EDGAR (CORRESPONDENCE) AND E-MAIL Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: BioPharmX Corporation Registration Statement on Form S-4 Registration No. 333-236526 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioPharmX Corporation (“Company”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-4 be accelerated to 2:00 p.m., Washington, D.C. time, on Tuesday, March 31, 2020, or as soon thereafter as is practicable. The Company hereby acknowledges and confirms its understanding that the Company and its management are responsible for the accuracy and adequacy of the disclosure in the Registration Statement, notwithstanding any review, comments, action or absence of action by the staff of the SEC. Please call Andrew Schwartz (at 954-468-2452) at Akerman LLP as soon as the Registration Statement has been declared effective. Thank you for your courtesy and cooperation. Very Truly Yours, /s/ Steven M. Bosacki Steven M. Bosacki Chief Executive Officer Cc: Chris Edwards (SEC) Andrew E. Schwartz, Esq.